<DOC>
	<DOCNO>NCT02684396</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics TAK-648 administer single oral dose TAK-648 solution escalate dose level healthy participant .</brief_summary>
	<brief_title>Phase 1 , TAK-648 , Single-Rising Dose Study</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , single-center , single-dose study healthy participant . The study first TAK-648 study human design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) single dose TAK-648 healthy participant . The compound test study TAK-648 . TAK-648 test find safe well-tolerated single dose . This study measure much study drug get blood stream long take body get rid . Information side effect may occur also collect . This study randomize dose-rising study mean first group research participant assign chance receive either study drug placebo . Placebo solution look like study drug active ingredient . The low dose study drug placebo give 1st group participant ( 1st cohort ) high dose give next group dose study drug test . TAK-648 dose 5 sequential cohort escalate dos low dose give Cohort 1 high dos give subsequent cohort . Doses could adjust base available safety , tolerability , pharmacokinetic ( PK ) data . Approximately 40 healthy male female participant plan enrollment 8 subject plan ( 6 randomize TAK-648 2 randomized placebo ) cohort . The study include 5 cohort . This single-center trial conduct United States . The overall time participate study 45 day . Participants make multiple visit clinic , include one 5-day period confinement clinic . All participant contact telephone 14 day last dose study drug Day 84 ( +/-2 day ) follow-up assessment .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Is healthy adult male nonpregnant , nonlactating female . 2 . Is age 18 55 year , inclusive . 3 . Weighs least 55 kg ( 121 lb ) body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive . 4 . Has systolic blood pressure &gt; 90 ≤150 mm Hg diastolic blood pressure &gt; 60 ≤90 mm Hg Screening Checkin ( Day 2 ) . 5 . Has calculate creatinine clearance &gt; 60 mL/min Screening Checkin ( Day 2 ) . 1 . Has know hypersensitivity component formulation TAK648 , phosphodiesterase inhibitor Listerine strip . 2 . Has significant medical history currently uncontrolled clinical condition , may safe participant participate study , may impact participant 's ability participate study ; may influence absorption study drug , may potentially confound study result . 3 . Has history persistent , chronic intermittent nausea , vomit , diarrhea current recent ( within 6 month ) gastrointestinal disease would influence absorption drug 4 . Has diagnosis major depression , bipolar disorder , anxiety disorder receive medication treat psychological disorder within 1 year prior Screening . 5 . Has abnormal laboratory value suggest clinically significant underlying disease follow laboratory abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal . 6 . Use excluded medication , supplement , food product outline protocol . 7 . Use new medication course study include Followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>